23 May 2013
Keywords: Novartis, Serelaxin, Relaxin, RLX030, Acute heart failure, AHF
Article | 25 September 2012
Phase III study results released by Swiss drug major Novartis (NOVN: VX) yesterday show that its investigational drug RLX030 (serelaxin; ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 September 2012
22 May 2013
© 2013 thepharmaletter.com